ConductScience.org, home

Paper22580997

Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Benhamou Y and 31 others. Haematologica, 2012. Cited by 130 papers, by iCite.

Cite this record

ConductScience Library. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Papers, record 22580997. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22580997

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
PubMed
Journal
Haematologica
PubMed
Year
2012
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
130
iCite
Relative citation ratio, by iCite
4.86
iCite
Revised in PubMed
2021-10-21
PubMed

Authors32

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Benhamou YYgal
2Assié CCyrielle
3Boelle PYPierre-Yves
4Buffet MMarc
5Grillberger RRana
6Malot SSandrine
7Wynckel AAlain
8Presne CClaire
9Choukroun GGabriel
10Poullin PPascale
11Provôt FFrançois
12Gruson DDidier
13Hamidou MMohamed
14Bordessoule DDominique
15Pourrat JJacques
16Mira JPJean-Paul
17Le Guern VVéronique
18Pouteil-Noble CClaire
19Daubin CCédric
20Vanhille PPhilippe

Source PubMed

See all 32 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ADAM ProteinsMajor topic
Models, StatisticalMajor topic
Purpura, Thrombocytopenic, IdiopathicMajor topic
ADAMTS13 Protein
Adult
Aged
Cohort Studies
Female
Humans
Male
Middle Aged
Prognosis
ROC Curve
Registries
Reproducibility of Results

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118028268Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review.Transfusion2008https://conductscience.org/library/papers/18028268PubMed
27632812Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange.Ann Hematol1995https://conductscience.org/library/papers/7632812PubMed
316371021Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.Br J Haematol2006https://conductscience.org/library/papers/16371021PubMed
420955397Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura.Br J Haematol2010https://conductscience.org/library/papers/20955397PubMed
514982878Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.Blood2004https://conductscience.org/library/papers/14982878PubMed
619180136TTP/HUS: observational studies generate hypotheses that lead to randomized controlled trials.Kidney Int Suppl2009https://conductscience.org/library/papers/19180136PubMed
721657946Investigational drugs in thrombotic thrombocytopenic purpura.Expert Opin Investig Drugs2011https://conductscience.org/library/papers/21657946PubMed
817164349
Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.
Blood2007https://conductscience.org/library/papers/17164349PubMed
919586943Vascular endothelial ageing, heartbeat after heartbeat.Cardiovasc Res2009https://conductscience.org/library/papers/19586943PubMed
1018574040Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.Blood2008https://conductscience.org/library/papers/18574040PubMed
1119350168[Thrombotic thrombocytopenic purpura: experience in 18 cases and literature review].Rev Med Chil2008https://conductscience.org/library/papers/19350168PubMed
123203132Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.Biometrics1988https://conductscience.org/library/papers/3203132PubMed
133661582High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients.Am J Med1987https://conductscience.org/library/papers/3661582PubMed
1416574680Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome.Nephrol Dial Transplant2006https://conductscience.org/library/papers/16574680PubMed
1516398654Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome: a new index predicting response to plasma exchange.Br J Haematol2006https://conductscience.org/library/papers/16398654PubMed
1620032506Survival and relapse in patients with thrombotic thrombocytopenic purpura.Blood2010https://conductscience.org/library/papers/20032506PubMed
1718048471Arterial aging: pathophysiological principles.Vasc Med2007https://conductscience.org/library/papers/18048471PubMed
1810741917Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases.Ann Hematol2000https://conductscience.org/library/papers/10741917PubMed
1920378566Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.Haematologica2010https://conductscience.org/library/papers/20378566PubMed
209590492Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.J Clin Apher1998https://conductscience.org/library/papers/9590492PubMed

See all 34 referencesDownload CSV of references

Cited by68

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.

PMIDTitleJournalYearIn PapersSource
42812790Current standards and novel concepts in thrombotic thrombocytopenic purpura.Front Med (Lausanne)2026https://conductscience.org/library/papers/42812790PubMed
42747330Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.J Clin Apher2026https://conductscience.org/library/papers/42747330PubMed
42566758Mortality prediction in immune TTP remains challenging despite artificial intelligence advances.Blood Adv2026https://conductscience.org/library/papers/42566758PubMed
42527695Acute neurologic clinical manifestations and outcomes in children with thrombotic microangiopathies in paediatric intensive care units.Eur J Pediatr2026https://conductscience.org/library/papers/42527695PubMed
42431609Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP.Blood Adv2026https://conductscience.org/library/papers/42431609PubMed
42145720The landscape of ADAMTS13-related tests in thrombotic thrombocytopenic purpura: a review.Front Med (Lausanne)2026https://conductscience.org/library/papers/42145720PubMed
41991316[Caplacizumab combined with therapeutic plasma exchange, glucocorticoids, and rituximab for refractory thrombotic thrombocytopenic purpura: a case report and literature review].Zhonghua Xue Ye Xue Za Zhi2026https://conductscience.org/library/papers/41991316PubMed
41940237Epidemiology, therapy, and outcome of immune-mediated thrombotic thrombocytopenic purpura at population level in Germany.Res Pract Thromb Haemost2026https://conductscience.org/library/papers/41940237PubMed
41917368Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura with Caplacizumab.Methods Mol Biol2026https://conductscience.org/library/papers/41917368PubMed
41917366Treating Immune Thrombotic Thrombocytopenic Purpura with Therapeutic Plasma Exchange.Methods Mol Biol2026https://conductscience.org/library/papers/41917366PubMed
41613148Experience in emergency management of first-episode immune thrombotic thrombocytopenic purpura over the past 21 years: a single-center retrospective study.Front Immunol2025https://conductscience.org/library/papers/41613148PubMed
41001423Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic Microangiopathy.Case Rep Hematol2025https://conductscience.org/library/papers/41001423PubMed
40765928Genetic variants contribute to modulation of renal function in patients with immune thrombotic thrombocytopenic purpura.Blood Vessel Thromb Hemost2024https://conductscience.org/library/papers/40765928PubMed
40662571Anti-ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune-Mediated TTP.Am J Hematol2025https://conductscience.org/library/papers/40662571PubMed
40235949Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project).EClinicalMedicine2025https://conductscience.org/library/papers/40235949PubMed
39534187Systematic Review of Individual Patient Data COVID-19 Infection and Vaccination-Associated Thrombotic Microangiopathy.Kidney Int Rep2024https://conductscience.org/library/papers/39534187PubMed
39221451Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.Res Pract Thromb Haemost2024https://conductscience.org/library/papers/39221451PubMed
39209728Clinical, biological, prognostic characteristics of patients with immune-mediated thrombotic thrombocytopenic purpura and Sjögren's disease.RMD Open2024https://conductscience.org/library/papers/39209728PubMed
39095866Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan.Thromb J2024https://conductscience.org/library/papers/39095866PubMed
38651093A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.Res Pract Thromb Haemost2024https://conductscience.org/library/papers/38651093PubMed

See all 68 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ADAMTS1311093PubTator's text mininghttps://conductscience.org/library/genes/11093

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/22580997

GET https://conductscience.org/api/papers/v1/22580997/authors?page=2